CTYPE html> BacVacDB | Administration route

Browse by administration route

This page shows data for Subcutaneous administration route.
Total Entries Retrieved: 26
IDName of the vaccineDisease nameName of bacteriaType of vaccineName of the manufacturerClinical Phase statusRoute of administrationPubMed identifierClinical trial number
1111 PBT Botulism Clostridium botulinum Toxoid Michigan Department of Public Health (MDPH) Clinical - Discontinued Subcutaneous 19837283 NA
1129 Menomune Meningococcal disease Neisseria meningitidis Polysaccharide Sanofi Pasteur Inc. Approved Subcutaneous NA NA
1135 Mencevax ACWY Meningococcal disease Neisseria meningitidis Subunit GlaxoSmithKline Biologicals Approved Subcutaneous NA NA
1136 Quadri Meningo Meningococcal disease Neisseria meningitidis Polysaccharide Biomed Labs Approved Subcutaneous NA NA
1168 Q-VAX Q Fever Coxiella burnetii Inactivated Seqirus Pty Ltd Approved Subcutaneous NA NA
1206 Spirolept Leptospirosis Leptospira genus Inactivated Imaxio Clinical - Phase 4 Subcutaneous NA NCT03497572
1229 NDBR 105 Q Fever Coxiella burnetii Inactivated U.S. Army Medical Research and Development Command Clinical - Withdrawn Subcutaneous NA NCT02092142
1230 Chloroform-methanol residue (CMR) Q Fever Coxiella burnetii Inactivated NA Clinical Subcutaneous 8454328 NA
1244 BK1310 Diphtheria Corynebacterium diphtheriae Combination Mitsubishi Tanabe Pharma Corporation Clinical - Phase 3 Subcutaneous NA NCT03891758
1266 Squarekids Diphtheria Corynebacterium diphtheriae Combination Kitasato Daiichi Sankyo Vaccine Co., Ltd. Clinical - Discontinued Subcutaneous NA NCT02907216
1268 BK1301 Diphtheria Corynebacterium diphtheriae Combination Mitsubishi Tanabe Pharma Corporation Clinical - Phase 3 Subcutaneous NA NCT02118961
1269 DTBIK Diphtheria Corynebacterium diphtheriae Toxoid Mitsubishi Tanabe Pharma Corporation Clinical - Phase 3 Subcutaneous NA NCT02118961
1273 Tetrabik Diphtheria Corynebacterium diphtheriae Combination Merck Sharp & Dohme Corp. Clinical - Phase 4 Subcutaneous NA NCT01926015
1277 Squarekids Pertussis (Whooping Cough) Bordetella pertussis Combination Kitasato Daiichi Sankyo Vaccine Co., Ltd. Clinical - Discontinued Subcutaneous NA NCT02907216
1283 BK1301 Pertussis (Whooping Cough) Bordetella pertussis Combination Mitsubishi Tanabe Pharma Corporation Clinical - Phase 3 Subcutaneous NA NCT02118961
1284 DTBIK Pertussis (Whooping Cough) Bordetella pertussis Toxoid Mitsubishi Tanabe Pharma Corporation Clinical - Phase 3 Subcutaneous NA NCT02118961
1291 BK1310 Pertussis (Whooping Cough) Bordetella pertussis Combination Mitsubishi Tanabe Pharma Corporation Clinical - Phase 3 Subcutaneous NA NCT03891758
1292 Tetrabik Pertussis (Whooping Cough) Bordetella pertussis Combination Merck Sharp & Dohme Corp. Clinical - Phase 4 Subcutaneous NA NCT01926015
1296 Squarekids Tetanus (Lock Jaw) Clostridium tetani Combination Kitasato Daiichi Sankyo Vaccine Co., Ltd. Clinical - Discontinued Subcutaneous NA NCT02907216
1298 Tetrabik Tetanus (Lock Jaw) Clostridium tetani Combination Merck Sharp & Dohme Corp. Clinical - Phase 4 Subcutaneous NA NCT01926015
1305 BK1301 Tetanus (Lock Jaw) Clostridium tetani Combination Mitsubishi Tanabe Pharma Corporation Clinical - Phase 3 Subcutaneous NA NCT02118961
1309 SP0204 Tetanus (Lock Jaw) Clostridium tetani Combination Sanofi Pasteur, a Sanofi Company Clinical - Phase 3 Subcutaneous NA NCT02274285
1310 DD 687 or DF 098 Tetanus (Lock Jaw) Clostridium tetani Combination Sanofi Pasteur, a Sanofi Company Clinical - Phase 3 Subcutaneous NA NCT02274285
1316 BK1310 Tetanus (Lock Jaw) Clostridium tetani Combination Mitsubishi Tanabe Pharma Corporation Clinical - Phase 3 Subcutaneous NA NCT03891758
1337 Meningo A+C Meningococcal disease Neisseria meningitidis Polysaccharide Sanofi Pasteur, a Sanofi Company Clinical - Phase 4 Subcutaneous NA NCT01430611
1338 Meng Ling Kang Meningococcal disease Neisseria meningitidis Polysaccharide Sanofi Pasteur, a Sanofi Company Clinical - Phase 4 Subcutaneous NA NCT01430611